Several carcinomas including gastric cancer have been reported to contain BI836845, a humanized insulin-like growth factor (IGF) ligand-neutralizing antibody, was used for IGF-related signalling pathway inhibition. AGS-EBV cells showed slower proliferating rate and higher sensitivity to BI836845 compared to AGS cells. Moreover, invasiveness of AGS-EBV was increased than that of AGS, and BI836845 treatment significantly decreased the invasiveness of AGS-EBV.
EBV, the focus of this study, was first detected in a Burkitt's lymphoma cell line. Since then, many studies have found EBV to be associated with several well-known human malignancies such as nasopharyngeal carcinoma (NPC), Hodgkin's lymphoma and EpsteinBarr virus-associated gastric cancer (EBVaGC). 3, 4 Incidence of EBVaGC is reported to be approximately 10% of globally detected gastric cancers. In addition, clinicopathological characteristics such as undifferentiated type 5 and CpG island hypermethylation 6 are reported to be high in EBVaGC. Prognosis of EBVaGC is also better than that of EBV-negative cases because lymph node metastasis in EBVaGC is significantly less frequent than in EBV-negative gastric cancer. 7 Many studies characterizing EBVaGC have been reported since the 1990s. 8 Most studies have focused on finding EBV-specific genes and their biological functions, 9,10 related microRNAs 11, 12 and chemo-resistance mechanisms. 13, 14 Recently, high-throughput assays were attempted to uncover regulatory mechanisms in EBVaGC. 15 However, only a few studies on target-specific pathways in
EBVaGC have been reported. One report has suggested that sequential combination is needed to improve the sensitivity of 5-fluororacil, one of adjuvant therapy agents in solid tumour, sensitivity when using PI3K inhibitors in EBV-positive gastric cancer cell lines. 16 Several studies have suggested that the insulin-like growth factor-1 receptor (IGF-1R) pathway is an essential target of EBV-positive cancer such as NPC. 17 IGF-related ligands (IGF-1, IGF-2 and insulin) and insulin-like growth factor binding proteins (IGFBPs) are produced the liver that are stimulated by growth hormone (GH).
Mainly, a complex of circulating IGFBPs and acid-labile subunit (ALS) prolongs the half-life of IGF-related ligands and delivers them to a complete receptor. Activated IGF-1R by IGF-1 and IGF-2 plays a critical role in proliferation, migration and invasion.
Many cancers express IGF-1R and 75.2% of stomach cancer tissue expresses IGF-1R, which may be the cause of poor prognosis. 18 Several IGF-1R-targeted drugs were developed based on the importance of the IGF-1R signalling pathway, but few proved to be effective. Considerable biological restrictions of IGF-1R are the reasons why development of IGF-1R pathway-targeting drugs has been difficult. 19 The major problem of targeting IGF-1R lies in its sequence similarity to the insulin receptor, which may lead to metabolic dysfunction. Mainly, insulin receptor isoform A (IR-A) activated by IGF-2 is known to promote oncogenic signalling. To overcome blocking that action without interfering the insulin axis insulin receptor activation, BI836845
(Xentuzumab), a drug that targets both IGF-1 and IGF-2, was developed and there are many ongoing clinical trials on various type of tumour. 20 In this study, we investigated the IGF-1R pathway and related biological roles in EBVaGC using BI836845. We also compared biological changes after IGF-1R signalling pathway inhibition in AGS and AGS-EBV cell lines. foetal bovine serum containing 100 Units/mL penicillin and 100 μg/ mL streptomycin. AGS-EBV cells were cultured in the same culture medium with the addition of 400 μg/mL G418 (A.G. Scientific, San Diego). Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 .
| Proliferation assay
For proliferation assays, 2.0 × 10 3 cells were seeded in 24-well plates. The wells were filled with fresh media and 10 μg/mL BI836845 the day after seeding and repeated every 3 days. Samples from triplicate wells were harvested every day, and cells were counted after Trypan blue staining. Growth curves were plotted as cell numbers versus time.
| Cell viability
Cell viability was determined using a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer's instructions. Briefly, 5.0 × 10 4 cells were seeded in 96-well plates and incubated for 24 hours. Serial diluent of BI836845 (0, 0.01, 0.1, 1, 10, 100 μg/mL) was treated to each well for 72 hours.
Next, 10 μL of CCK-8 solution was added to each well and incubated for 2 hours at 37°C. Absorbance was determined at 450 nm using microplate reader (TECAN, Männedorf, Switzerland).
| Invasion assay
Trans-well invasion chambers were pre-coated with 500 ng/mL Matrigel (Corning, Corning, USA) for 6 hours. The medium at the bottom of the 24-well plate was replaced with fresh medium containing 10% FBS, and 2 × 10 4 cells in serum free media were added to the top chamber. After incubation for 24 hours at 37°C, the cells were then fixed with 4% formaldehyde for 2 minutes. The chambers were then washed with PBS and stained with 1% crystal violet for 10 minutes. After cleaning and drying the chamber membrane, cells were counted using an inverted microscope (Zeiss, Oberkochen,
Germany). reverse, 5′-AGAAGCCTCGATGGTCACAATT-3′; and GAPDH forward, 5′-CCATGGAGAAGGCTGGGG-3′, and reverse, 5′-CAAAGT TGTCATGGATGACC-3′. PCR was performed on a thermal cycler (Eppendorf, Hamburg, Germany) using the appropriate annealing temperature. PCR products were examined using agarose gel electrophoresis and exposed to a UV detector to confirm the presence of a single amplification product.
| RT-PCR

| ELISA
Concentration of IGF-1 and IGF-2 was measured using human ELISA kit (Abnova, Taipei City, Taiwan) according to the manufacturer′s instructions. For the sample preparation, 2.5 μg of total lysate protein and 5 μg of total secreted protein were quantified by BCA assay. Finally, concentration of IGF-1 and IGF-2 was calculated at 450 nm using a microplate reader.
| Western blotting
For Western blotting, control and BI836845-treated cells were collected 24 hours after treatment. A total of 30 μg of whole cell protein extracts in RIPA lysis buffer were size-fractionated using 10% SDS polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules). Membranes were blocked with 5% non-fat dry milk/TBS-T for 1 hour at room temperature and then incubated overnight with primary antibodies at 4°C. Membranes were washed five times with TBS-T and incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature. Blots were washed five times again, and protein signals were enhanced and detected using a chemiluminescence detection kit (Santa Cruz, Dallas). The intensity of the bands was normalized using α-tubulin with ImageJbased quantification. 
| Flow cytometry
| Statistical analysis
Continuous data were analysed using the Student t test. Differences were considered statistically significant when P < 0.05. The significance of dose-or time-dependent change was calculated by twoway ANOVA with the use of IBM SPSS statistics.
| RESULTS
| Expression of IGF-related genes and proteins in EBVaGC
To evaluate IGF-related gene and protein expression, the baseline expression levels in AGS and AGS-EBV cells were first determined.
Comparing AGS and AGS-EBV cells, no significant differences in the mRNA levels of IGF-1R, IGF-1, IGF-2 and IGFBP-6 were observed.
Interestingly, IGFBP-3 mRNA levels in AGS-EBV cells were 74.6 ± 28.8%, which was higher than those in AGS cells ( Figure 1A ).
Western blot analysis showed that, although total IGF-1R protein levels in AGS-EBV were 17.4 ± 28.8% lower than those in AGS cells, phospho-IGF-1R levels were 38.9 ± 28.1% higher than those in AGS JEONG ET AL. The results show that IGFBP-3, secreted IGF-1 and lysate IGF-2 expression levels were increased, and phospho-IGF-1R was more activated, in AGS-EBV cells. With the exception of the aforementioned factors, the expression levels of most IGF-related factors were decreased in AGS-EBV.
| Effect of BI836845 on proliferation, sensitivity and invasion of AGS and AGS-EBV cells
To evaluate the effect of EBV infection on AGS cells, proliferation assay was first performed. On days 6 and 7, proliferating AGS cells were at significantly higher number than AGS-EBV cells (P < 0.01 and P < 0.001 at days 6 and 7, respectively; Figure 2A ). We then and IGFBP-6 was observed ( Figure 3A ).
As can be seen in Figure 3B , phospho-IGF-1R levels were markedly reduced after BI836845 treatment in both AGS and AGS-EBV To investigate the expression levels of intracellular EMT-related molecules, which are associated with the ability for invasion, we examined the protein expression of E-cadherin, Snail and vimentin.
Despite the very low E-cadherin levels observed, no significant differences were detected between the control and BI836845-treated groups. Snail, which inhibits the activation of E-cadherin, showed higher expression levels in AGS than in AGS-EBV cells. In addition, neither AGS nor AGS-EBV treatment groups showed any changes in Snail levels after treatment. Compared to both control groups, vimentin expression levels in AGS-EBV were reduced after BI836845 treatment, whereas those in AGS remained unchanged ( Figure 3D ).
Vimentin expression was down-regulated after BI836845 treatment in AGS-EBV but not in AGS cells. We hereby conjectured that the ability to invade may be regulated by vimentin expression in AGS-EBV cells independently of E-cadherin and Snail.
| Apoptosis or cell cycle arrest was not observed after BI836845 treatment in AGS-EBV
We performed Annexin V/PI double-staining assay to determine whether the reduction in cell viability was induced by apoptosis. As shown in Figure 4A , the proportion of cell death in AGS-EBV cells was approximately 4 times greater than that in AGS cells. Neither AGS nor AGS-EBV cells showed any increment in apoptosis after treatment with 10 μg/mL BI836845.
When we performed cell cycle analysis using PI staining, no significant cell cycle arrest was observed in AGS and AGS-EBV cells after BI836845 treatment ( Figure 4B ). Baseline sub-G1 proportion was approximately 1.0% for both cell lines (AGS and AGS-EBV).
Specifically for AGS-EBV, both control and BI836845 treated group increased to a 3.0% sub-G1 proportion at 48 hours.
These results indicate that the reduction in proliferation in AGS-EBV compare to AGS may be influenced by the increase in natural cell death. However, inhibition of proliferation and cell viability in BI836845-treated AGS-EBV cells resulted neither from apoptotic cell death nor from cell cycle arrest. | 5903
| BI836845 inhibits progression of AGS-EBV cells into S phase
To further investigate the possible mechanism of proliferation inhibition, we performed cell cycle analysis with G0/G1 synchronization using serum starvation, because no cell cycle arrest could be observed in normal culture conditions. After synchronization, the G0/G1 proportion in AGS and AGS-EBV cells was 62.0% and 58.2%, respectively. Interestingly, cell cycle progression of AGS-EBV cells was faster than that of AGS cells ( Figure 5A ). Figure 3D ). This suggests that vimentin might play an independent role in the regulation of AGS-EBV cell invasiveness.
As mechanistic studies of IGFBP-3 and IGFBP-6 were not accomplished in our study, future studies will be needed to evaluate the intra-and extracellular functional activity. 
